Gradient Boosting Machine Based on PSO for prediction of Leukemia after a Breast Cancer Diagnosis

The purpose of this study is to develop an accurate risk predictive model for Chronic Myeloid Leukemia (CML) after an early diagnosis of Breast Cancer (BC). Gradient Boosting Machine (GBM) classification algorithm has been applied to the SEER breast cancer dataset for females diagnosed with BC from 2010 to 2016. A practical Swarm optimizer (PSO) was utilized to optimize the GBM algorithm's hyperparameters to find the SEER dataset's best attributes. Nine attributes were carefully selected to study the growth of CML after a lag time of 6 months following BC's diagnosis. The results revealed that the predictive model could classify patients with breast cancer only and patients with breast cancer with Leukemia by an achieved Accuracy, Sensitivity, and Specificity rates of 98.5 %, 99 %, 97.85 %, respectively. To verify the performance of the proposed algorithm, the accuracy of the suggested GBM classifier model was compared with another state-of-the-art model classifiers KNN (k-Nearest Neighbor), SVM (Support Vector Machine), and RF (Random Forest), which are commonly applied algorithms in most of the existing literature. The results also proved the superior ability of the implemented GBM model Classifier in the classification of breast cancer disease and prediction of patients having Leukemia developed after having breast cancer. These results are promising as they show the integral role of the GBM classifier to classify and predict the tumor with high accuracy and efficiency, which will further help in better cancer diagnosis and treatment of the disease.

[1]  H. Hwang,et al.  A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma , 2020, Annals of laboratory medicine.

[2]  G. Lenhart,et al.  Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. , 2018, Gynecologic oncology.

[3]  H. Kaplan,et al.  Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders. , 2020, The oncologist.

[4]  I. Lalya,et al.  Acute Myeloid Leukemia After Treatment of Early Breast Cancer: Case Report and Literature Review , 2019, Indian Journal of Gynecologic Oncology.

[5]  R. Khodarahmi,et al.  Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature , 2015, Iranian journal of cancer prevention.

[6]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[7]  M. Castiglione‐Gertsch,et al.  Leukemia risk after adjuvant treatment of early breast cancer. , 2005, Women's health.

[8]  V. Raina,et al.  Treatment Related Acute Myeloid Leukemia in Breast Cancer Survivors: A Single Institutional Experience , 2019, Indian Journal of Hematology and Blood Transfusion.

[9]  Aseem Patil,et al.  Detection of Real Time Objects Using TensorFlow and OpenCV , 2019 .

[10]  Anas M. Saad,et al.  Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study. , 2019, Current problems in cancer.

[11]  J. Bergh,et al.  Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer , 2017, Breast Cancer Research and Treatment.

[12]  Qing Guo,et al.  Improved Particle Swarm Optimization Using Wolf Pack Search , 2019 .

[13]  Breast Cancer Detection using Gradient Boost Ensemble Decision Tree Classifier , 2019 .

[14]  Evangelos Spiliotis,et al.  Statistical and Machine Learning forecasting methods: Concerns and ways forward , 2018, PloS one.

[15]  Jay-ar P. Lalata,et al.  Comparison of Machine Learning Algorithms in Breast Cancer Prediction Using the Coimbra Dataset , 2019, International journal of simulation: systems, science & technology.

[16]  J. Fay,et al.  Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. , 2018, Leukemia research.